| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.
|
Kidney Int
|
2011
|
5.25
|
|
2
|
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.
|
Lancet
|
2012
|
5.10
|
|
3
|
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis.
|
Lancet
|
2012
|
4.75
|
|
4
|
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy.
|
Kidney Int
|
2008
|
3.27
|
|
5
|
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes.
|
Diabetes Care
|
2003
|
3.12
|
|
6
|
Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study.
|
BMJ
|
2004
|
2.62
|
|
7
|
Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy.
|
Kidney Int
|
2011
|
2.52
|
|
8
|
Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study.
|
J Hypertens
|
2007
|
2.27
|
|
9
|
Urinary proteomics in diabetes and CKD.
|
J Am Soc Nephrol
|
2008
|
2.12
|
|
10
|
Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
|
Diabetes Care
|
2003
|
2.08
|
|
11
|
Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients.
|
Diabetes Care
|
2010
|
2.06
|
|
12
|
Progression of nephropathy in type 2 diabetic patients.
|
Kidney Int
|
2004
|
2.05
|
|
13
|
New susceptibility loci associated with kidney disease in type 1 diabetes.
|
PLoS Genet
|
2012
|
1.79
|
|
14
|
Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study.
|
Diabetes
|
2009
|
1.76
|
|
15
|
Recommendations for biomarker identification and qualification in clinical proteomics.
|
Sci Transl Med
|
2010
|
1.59
|
|
16
|
Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy.
|
Kidney Int
|
2005
|
1.52
|
|
17
|
Development and validation of GFR-estimating equations using diabetes, transplant and weight.
|
Nephrol Dial Transplant
|
2009
|
1.46
|
|
18
|
Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
|
Diabetes
|
2010
|
1.44
|
|
19
|
Beneficial impact of spironolactone in diabetic nephropathy.
|
Kidney Int
|
2005
|
1.40
|
|
20
|
Urinary proteomics for early diagnosis in diabetic nephropathy.
|
Diabetes
|
2012
|
1.38
|
|
21
|
Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
|
Diabetes Care
|
2011
|
1.34
|
|
22
|
Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.
|
Diabetes Care
|
2009
|
1.33
|
|
23
|
Vitamin D levels, microvascular complications, and mortality in type 1 diabetes.
|
Diabetes Care
|
2011
|
1.28
|
|
24
|
YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria.
|
Diabetes Care
|
2008
|
1.23
|
|
25
|
Tubular and glomerular injury in diabetes and the impact of ACE inhibition.
|
Diabetes Care
|
2009
|
1.23
|
|
26
|
Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
|
Diabetes Care
|
2006
|
1.21
|
|
27
|
Vitamin D levels and mortality in type 2 diabetes.
|
Diabetes Care
|
2010
|
1.21
|
|
28
|
Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate.
|
Diabetes Care
|
2008
|
1.18
|
|
29
|
initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial.
|
Diabetes Care
|
2011
|
1.18
|
|
30
|
Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy.
|
Diabetes Care
|
2008
|
1.18
|
|
31
|
Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.
|
Diabetes Care
|
2010
|
1.14
|
|
32
|
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.
|
J Am Soc Nephrol
|
2008
|
1.12
|
|
33
|
Elevated levels of high-molecular-weight adiponectin in type 1 diabetes.
|
J Clin Endocrinol Metab
|
2008
|
1.12
|
|
34
|
Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy.
|
PLoS One
|
2010
|
1.12
|
|
35
|
Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals.
|
J Hypertens
|
2010
|
1.09
|
|
36
|
Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study.
|
Curr Diab Rep
|
2013
|
1.09
|
|
37
|
Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
|
Diabetes Care
|
2007
|
1.07
|
|
38
|
Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study.
|
Kidney Int
|
2005
|
1.06
|
|
39
|
Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes.
|
Clin Chem
|
2011
|
1.05
|
|
40
|
Vitamin D levels and asymptomatic coronary artery disease in type 2 diabetic patients with elevated urinary albumin excretion rate.
|
Diabetes Care
|
2011
|
1.04
|
|
41
|
The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy.
|
Proteomics Clin Appl
|
2008
|
1.01
|
|
42
|
Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients.
|
Diabetes Res Clin Pract
|
2012
|
1.01
|
|
43
|
Serum uric acid as a new player in the development of diabetic nephropathy.
|
J Ren Nutr
|
2011
|
1.00
|
|
44
|
Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study.
|
Scand J Clin Lab Invest
|
2008
|
1.00
|
|
45
|
Implementation of proteomic biomarkers: making it work.
|
Eur J Clin Invest
|
2012
|
1.00
|
|
46
|
Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study.
|
PLoS One
|
2008
|
0.98
|
|
47
|
Urinary neutrophil gelatinase-associated lipocalin and progression of diabetic nephropathy in type 1 diabetic patients in a four-year follow-up study.
|
Nephron Clin Pract
|
2010
|
0.97
|
|
48
|
Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy.
|
Diabetes Care
|
2010
|
0.96
|
|
49
|
Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes.
|
Diabetes Care
|
2012
|
0.95
|
|
50
|
Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy.
|
Diabetes Care
|
2005
|
0.95
|
|
51
|
Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy.
|
Proteome Sci
|
2010
|
0.95
|
|
52
|
Osteoprotegerin and mortality in type 2 diabetic patients.
|
Diabetes Care
|
2010
|
0.94
|
|
53
|
Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.
|
Diabetes
|
2006
|
0.93
|
|
54
|
Cardiovascular autonomic neuropathy and subclinical cardiovascular disease in normoalbuminuric type 1 diabetic patients.
|
Diabetes
|
2012
|
0.93
|
|
55
|
Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology.
|
PLoS One
|
2010
|
0.89
|
|
56
|
Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function.
|
Platelets
|
2010
|
0.88
|
|
57
|
Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria.
|
Cardiovasc Diabetol
|
2011
|
0.88
|
|
58
|
Diabetes mellitus, hypertension and albuminuria in rural Zambia: a hospital-based survey.
|
Trop Med Int Health
|
2013
|
0.87
|
|
59
|
Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate.
|
Nephrol Dial Transplant
|
2011
|
0.87
|
|
60
|
NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis.
|
Cardiovasc Diabetol
|
2011
|
0.86
|
|
61
|
NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients.
|
Cardiovasc Diabetol
|
2012
|
0.86
|
|
62
|
Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients.
|
J Diabetes Complications
|
2012
|
0.86
|
|
63
|
Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy.
|
J Renin Angiotensin Aldosterone Syst
|
2011
|
0.86
|
|
64
|
The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP.
|
Scand J Clin Lab Invest
|
2012
|
0.85
|
|
65
|
Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.
|
BMC Nephrol
|
2010
|
0.85
|
|
66
|
Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study.
|
Diabetologia
|
2014
|
0.84
|
|
67
|
Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?
|
J Hypertens
|
2013
|
0.84
|
|
68
|
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.
|
Clin J Am Soc Nephrol
|
2011
|
0.84
|
|
69
|
Tonometric devices for central aortic systolic pressure measurements in patients with type 1 diabetes: comparison of the BPro and SphygmoCor devices.
|
Blood Press Monit
|
2013
|
0.84
|
|
70
|
Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity.
|
Platelets
|
2009
|
0.83
|
|
71
|
Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
|
Kidney Int
|
2002
|
0.83
|
|
72
|
Urinary adiponectin excretion rises with increasing albuminuria in type 1 diabetes.
|
J Diabetes Complications
|
2013
|
0.83
|
|
73
|
Proteomic biomarkers in diabetic nephropathy--reality or future promise?
|
Nephrol Dial Transplant
|
2010
|
0.83
|
|
74
|
Smoking and progression of diabetic nephropathy in type 1 diabetes.
|
Diabetes Care
|
2003
|
0.83
|
|
75
|
Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy.
|
Kidney Int
|
2004
|
0.83
|
|
76
|
SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes.
|
Diabetologia
|
2014
|
0.82
|
|
77
|
Finding diabetic nephropathy biomarkers in the plasma peptidome by high-throughput magnetic bead processing and MALDI-TOF-MS analysis.
|
Proteomics Clin Appl
|
2010
|
0.82
|
|
78
|
Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18 year follow-up study.
|
Diabetologia
|
2014
|
0.82
|
|
79
|
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
|
Am J Nephrol
|
2015
|
0.81
|
|
80
|
Optimal dose of losartan for renoprotection in diabetic nephropathy.
|
Nephrol Dial Transplant
|
2002
|
0.81
|
|
81
|
High YKL-40 levels predict mortality in patients with type 2 diabetes.
|
Diabetes Res Clin Pract
|
2011
|
0.81
|
|
82
|
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
|
Semin Nephrol
|
2004
|
0.81
|
|
83
|
24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes - a cross-sectional study.
|
Cardiovasc Diabetol
|
2013
|
0.80
|
|
84
|
Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease.
|
J Renin Angiotensin Aldosterone Syst
|
2012
|
0.80
|
|
85
|
Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients.
|
Clin Proteomics
|
2010
|
0.80
|
|
86
|
Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria.
|
Amino Acids
|
2011
|
0.80
|
|
87
|
Renoprotection with and without blood pressure reduction.
|
Kidney Int Suppl
|
2005
|
0.80
|
|
88
|
Renoprotective effects of renin-angiotensin-system inhibitors.
|
Lancet
|
2006
|
0.79
|
|
89
|
The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes.
|
J Negat Results Biomed
|
2011
|
0.79
|
|
90
|
Ambulatory tonometric blood pressure measurements in patients with diabetes.
|
Diabetes Technol Ther
|
2012
|
0.79
|
|
91
|
Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial.
|
Nephrol Dial Transplant
|
2009
|
0.79
|
|
92
|
Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?
|
Nephrol Dial Transplant
|
2006
|
0.79
|
|
93
|
Vitamin D status and 5-year changes in urine albumin creatinine ratio and parathyroid hormone in a general population.
|
Endocrine
|
2013
|
0.79
|
|
94
|
Endothelial progenitor cells in long-standing asymptomatic type 1 diabetic patients with or without diabetic nephropathy.
|
Nephron Clin Pract
|
2011
|
0.78
|
|
95
|
Systems biology to battle vascular disease.
|
Nephrol Dial Transplant
|
2010
|
0.78
|
|
96
|
Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes.
|
Diabetes Care
|
2006
|
0.78
|
|
97
|
Diabetes: Effect of vitamin D on diabetic kidney disease in T1DM.
|
Nat Rev Endocrinol
|
2012
|
0.78
|
|
98
|
Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients.
|
Cardiovasc Diabetol
|
2012
|
0.78
|
|
99
|
Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes.
|
J Hypertens
|
2015
|
0.78
|
|
100
|
Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy.
|
Nephrol Dial Transplant
|
2006
|
0.77
|
|
101
|
Telmisartan vs. enalapril in type 2 diabetes.
|
N Engl J Med
|
2005
|
0.77
|
|
102
|
Omics-bioinformatics in the context of clinical data.
|
Methods Mol Biol
|
2011
|
0.77
|
|
103
|
Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy.
|
Diabetes Care
|
2011
|
0.77
|
|
104
|
Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment.
|
Proteomics
|
2013
|
0.76
|
|
105
|
Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.
|
Nephrol Dial Transplant
|
2003
|
0.76
|
|
106
|
Assessment of kidney function: UACR--two risk markers or a 24 h collection in a minute?
|
Nat Rev Nephrol
|
2012
|
0.75
|
|
107
|
Follow-up of intensive glucose control in type 2 diabetes.
|
N Engl J Med
|
2009
|
0.75
|
|
108
|
Direct renin inhibition in chronic kidney disease.
|
Br J Clin Pharmacol
|
2013
|
0.75
|
|
109
|
Experimental testing of skin reactions to insulin detemir in diabetes patients naïve to insulin detemir.
|
Skin Res Technol
|
2011
|
0.75
|
|
110
|
Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study.
|
J Renin Angiotensin Aldosterone Syst
|
2012
|
0.75
|
|
111
|
[Hypertension in patients with diabetes].
|
Ugeskr Laeger
|
2009
|
0.75
|
|
112
|
Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
|
Nephrol Dial Transplant
|
2011
|
0.75
|
|
113
|
Treatment with continuous subcutaneous insulin infusion is associated with lower arterial stiffness.
|
Acta Diabetol
|
2014
|
0.75
|
|
114
|
Cuff inflations do not affect night-time blood pressure: comparison of 24 h ambulatory blood pressure measured by a cuff and a tonometric device in type 2 diabetes.
|
Blood Press Monit
|
2015
|
0.75
|
|
115
|
[Clinical assessment of excretory renal function].
|
Ugeskr Laeger
|
2009
|
0.75
|
|
116
|
[Renal disease by type 2 diabetes].
|
Ugeskr Laeger
|
2012
|
0.75
|
|
117
|
[ACE inhibitors and AT-II antagonists--do they protect against renal disease?].
|
Ugeskr Laeger
|
2006
|
0.75
|
|
118
|
[Clinical use of estimated glomerular filtration rate for evaluation of kidney function].
|
Ugeskr Laeger
|
2013
|
0.75
|
|
119
|
Discrepancy between tonometric ambulatory and cuff-based office blood pressure measurements in patients with type 1 diabetes.
|
J Clin Hypertens (Greenwich)
|
2012
|
0.75
|
|
120
|
Pulse wave reflection is associated with diabetes duration, albuminuria and cardiovascular disease in type 1 diabetes.
|
Acta Diabetol
|
2014
|
0.75
|
|
121
|
[Risk factors for the development of microalbuminuria in type 1 diabetes: an incidence cohort study--a secondary publication].
|
Ugeskr Laeger
|
2005
|
0.75
|